PT - JOURNAL ARTICLE AU - Blodgett, JM AU - Ahmadi, MN AU - Atkin, AJ AU - Chastin, S AU - Chan, HW AU - Suorsa, K AU - Bakker, EA AU - Hettiarcachchi, P AU - Johansson, PJ AU - Sherar, LB AU - Rangul, V AU - Pulsford, RM AU - Mishra, G AU - Eijsvogel, TMH AU - Stenholm, S AU - Hughes, AD AU - Teixeira-Pinto, AM AU - Eklund, U AU - Lee, IM AU - , AU - Holtermann, A AU - Koster, A AU - Stamatakis, E AU - Hamer, M TI - Device measured sedentary behaviour, sleep, light and moderate-vigorous physical activity and cardio-metabolic health: A compositional individual participant data analysis in the ProPASS consortium AID - 10.1101/2023.08.01.23293499 DP - 2023 Jan 01 TA - medRxiv PG - 2023.08.01.23293499 4099 - http://medrxiv.org/content/early/2023/08/02/2023.08.01.23293499.short 4100 - http://medrxiv.org/content/early/2023/08/02/2023.08.01.23293499.full AB - Background/Aims Physical inactivity, sedentary behaviour (SB) and inadequate sleep are key behavioural risk factors of cardiometabolic diseases; each is mainly considered in isolation. The study aim was to investigate associations of five movement behaviour compositions with adiposity and cardiometabolic biomarkers.Methods Cross-sectional data from 15,246 participants from the Prospective Physical Activity, Sitting and Sleep consortium (ProPASS) were analysed. Time spent in sleep, SB, standing, light-intensity physical activity (LIPA) and moderate-vigorous physical activity (MVPA) made up the composition. Outcomes included BMI, waist circumference, HDL cholesterol, total:HDL cholesterol ratio, triglycerides and HbA1c. Compositional linear regression examined associations between compositions and each outcome, including modelling reallocation of time between behaviours.Results The average daily composition of the sample(age:53.7±9.7years; 54.7%female) was 7.7hrs sleeping,10.4hrs sedentary,3.1hrs standing,1.5hrs LIPA and 1.3hrs MVPA. A greater proportion of MVPA time and smaller proportion of SB time was associated with better outcomes. Reallocating time from SB,standing,LIPA or sleep into MVPA had the largest theoretical improvement across all outcomes. For example, replacing 30min of SB, sleep, standing or LIPA with MVPA was associated with -0.63 (95%CI -0.48,-0.79), -0.43 (-0.25,-0.59), -0.40 (-0.25,-0.56) and -0.15 (0.05,-0.34)kg/m2 lower BMI, respectively. A larger proportion of standing time was beneficial for outcomes; sleep had a detrimental association when replacing LIPA or MVPA and positive association when replacing SB. The minimal displacement into MVPA for improved cardiometabolic health ranged from 3.8 (HbA1c) to 12.7 (triglycerides) min/day.Conclusions Compositional data analyses revealed a distinct hierarchy of behaviours. MVPA demonstrated the strongest, most time-efficient protective associations with cardiometabolic outcomes. Theoretical benefits from reallocating SB into sleep, standing or LIPA required substantial changes in daily activity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by a British Heart Foundation Special Grant (SP/F/20/150002), and National Health and Medical Research Council (Australia) Investigator (APP1194510) and Ideas (APP1180812) Grants. The establishment of the ProPASS consortium was supported by an unrestricted 2018-20 grant by PAL Technologies (Glasgow, UK). ActiPASS development was partly funded by FORTE, Swedish Research Council for Health, Working Life and Welfare (2021 01561). ES is funded by a National Health and Medical Research Council Investigator Grant (APP1194510). GDM is supported by a National Health and Medical Research Council Principal Research Fellowship (APP1121844). AH receives support from the British Heart Foundation, the Horizon 2020 Framework Programme of the European Union, the National Institute for Health Research University College London Hospitals Biomedical Research Centre, the UK Medical Research Council, the National Institute for Health Research, the Wellcome Trust, and works in a unit that receives support from the UK Medical Research Council.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University College London ethics committee gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors